Re:Thinking with Adam GrantThe science of living longer with Eric Topol | ReThinking with Adam Grant
CHAPTERS
- 0:00 – 1:28
Eric Topol’s early communication quirks and breakfast as a healthspan baseline
Eric Topol and Adam Grant open with personal anecdotes about Topol’s childhood and his identity as a lifelong writer. They pivot into a concrete, relatable entry point—what Topol eats for breakfast—and why it’s a solid evidence-based choice.
- •Topol’s late speech development and note-writing habit as a kid
- •Grant’s surprise at Topol’s prolific output and communication skills
- •Breakfast breakdown: non-fat Greek yogurt, berries, low-sugar granola
- •Why this meal works: protein, low added sugar, nutrient-dense berries
- 1:28 – 3:28
The ‘wellderly’ study: extreme health without obvious genetic advantages
Topol explains the ambitious “wellderly” project: finding people 85+ who reached old age with virtually no disease, no medications, and intact cognition. Whole-genome sequencing yielded an unexpected result—few meaningful genetic differences compared to typical older adults with chronic disease.
- •Definition of “wellderly”: 85–102, disease-free, no meds, cognitively intact
- •Seven-year effort to recruit 1,400 participants and sequence genomes
- •Surprising null finding: genomes largely similar to controls with chronic disease
- •Implication: extreme healthspan isn’t easily explained by DNA variants alone
- 3:28 – 4:19
If not genes, then what? Immune aging, inflammation, and lifestyle’s limits
After the genetics surprise, the conversation reframes longevity as driven more by immune system aging and inflammation than by straightforward inherited advantages. Lifestyle matters, but Topol cautions that biology—especially immunosenescence—may be the deeper determinant shaping outcomes.
- •Grant’s inference: longevity may be more controllable than assumed
- •Topol’s nuance: lifestyle helps, but immune aging/inflammation may dominate
- •Immunosenescence as a candidate mechanism behind “wellderly” outcomes
- •Lifestyle as an input into biological drivers rather than the whole story
- 4:19 – 6:23
The longevity boom: real biotech progress mixed with rampant pseudoscience
Grant and Topol discuss the explosion of the longevity industry and the surge of questionable products and claims. Topol describes why he felt compelled to write a book: to separate hard evidence from hype, especially as clinics, influencers, and billionaire-backed ventures amplify noise.
- •Longevity interest creates a market for “prey” and predatory marketing
- •Longevity clinics, supplements, and influencer claims often lack evidence
- •Legitimate biotech is also advancing and fuels genuine excitement
- •Billionaire investment accelerates both innovation and hype
- 6:23 – 9:21
Topol’s debunking list: supplements, longevity clinics, full-body MRI, rapamycin, and protein hype
Topol runs through prominent examples of longevity snake oil and overconfident interventions. He explains why several popular tactics can be useless or harmful—particularly when they lead to invasive follow-ups or immune suppression without human evidence of benefit.
- •Anti-aging supplements: big claims, little meaningful supportive data
- •Longevity clinics: expensive protocols (e.g., plasmapheresis, hyperbaric oxygen, stem cells)
- •Total-body MRI for healthy people: false alarms and risky downstream procedures
- •Rapamycin: mouse data ≠ human evidence; risk of immune suppression and downstream harms
- •“Bro science” protein dosing: excessive animal protein may increase inflammation and atherosclerosis risk
- 9:21 – 12:12
Vitamins vs. supplements: when (if ever) they’re worth it
Topol differentiates between routine vitamin use and the broader supplement market. For most healthy people with a solid diet, vitamins add little; targeted supplementation can be appropriate when a clinician identifies a true deficiency, while many supplements provide questionable value.
- •Healthy diet usually eliminates the need for routine vitamins
- •Small/marginal evidence for multivitamins; generally low upside
- •Targeted supplementation (e.g., vitamin D, B12) when deficiency is confirmed
- •Some trials suggest harms for specific vitamins in specific contexts
- •Fish oil: dietary omega-3 evidence is stronger than supplement evidence; often expensive for minimal benefit
- 12:12 – 13:12
Why people keep taking supplements anyway: distrust, placebo effects, and behavior change barriers
Even with weak evidence, Topol notes patients often remain committed to supplement stacks. He attributes persistence to distrust in the medical establishment, marketing pressure, and placebo effects—plus the psychological cost of removing something people believe is helping.
- •Growing rejection of mainstream medicine fuels self-directed supplement use
- •Clinicians often settle into a “neutral zone” when patients won’t stop
- •Placebo effects reinforce attachment (“I feel better, so it must work”)
- •Stopping a perceived-helpful behavior can feel like losing a benefit
- 13:12 – 15:25
A prevention-first blueprint: stopping the ‘big three’ diseases with a 20-year runway
Topol lays out the core thesis: medicine can meaningfully extend healthspan by preventing Alzheimer’s/neurodegeneration, cancer, and cardiovascular disease. The key is recognizing these diseases often develop over decades, creating a long window to identify risk early and intervene.
- •Focus on preventing: neurodegenerative disease, cancer, cardiovascular disease
- •Disease development commonly takes ~20 years before clinical manifestation
- •Modern tools can identify high-risk individuals earlier than traditional methods
- •Lifestyle factors remain important but are part of a broader prevention system
- •Advances in the biology of aging are driving new prevention possibilities
- 15:25 – 18:21
Early detection done right: why full-body MRI fails and blood-based cancer detection may win
Grant challenges the apparent tension between Topol’s MRI skepticism and his enthusiasm for early intervention. Topol clarifies that full-body MRI detects late-stage masses, while emerging blood tests can detect microscopic tumor DNA earlier—sometimes early enough for the immune system (or immunotherapy) to eliminate it.
- •MRI-detected masses often imply billions of cells and possibly spread
- •Blood tests can detect tiny amounts of tumor DNA earlier than imaging
- •Some early tumor-DNA signals appear to resolve—immune system may clear them
- •Potential to ‘rev up’ immunity to eliminate cancer before it establishes
- •Multi-cancer early detection tests are already orderable by physicians
- 18:21 – 21:02
From age-based screening to risk-based precision prevention (and why medicine resists)
Topol argues that cancer screening is overly age-driven and inefficient, urging a shift toward identifying the minority at genuinely elevated risk. He describes integrating health records, labs, genetics, and other markers—and notes institutional inertia and industry lobbying that slow adoption.
- •Age-based screening treats everyone the same despite uneven lifetime risk
- •Risk partitioning could focus screening where it’s most beneficial
- •Layered data approach: EHR, labs, imaging history, genetics, biomarkers
- •Polygenic risk scores and genome data can flag elevated risk groups
- •Resistance comes from slow-changing practice norms and vested interests
- 21:02 – 23:06
Exercise guidance without the zone wars: move more, and train strength + balance too
Topol downplays over-optimization of heart-rate “zones” in favor of consistent movement. He emphasizes a balanced routine that includes aerobic activity, resistance training, and balance work—especially important with age-related declines in proprioception and fall risk.
- •Best evidence: consistent physical activity matters more than perfect zones
- •Extreme exercise may not confer ‘extreme’ benefit and could be harmful
- •Aerobic training is valuable, but resistance training is essential too
- •Balance training becomes increasingly important with aging
- •Adherence strategies: make it enjoyable (music, TV, friends)
- 23:06 – 27:21
Scientific skepticism and the AI era: becoming an informed patient without drowning in misinformation
Topol describes how he evaluates claims: distrust initial assertions, demand rigorous proof, and look for replication. He and Grant then explore how generative AI can help patients triangulate information—while acknowledging risks for anxious users and the need for trusted clinician oversight.
- •Core method: challenge dogma; require rigorous, replicated evidence
- •Internet abundance increased both access to information and misinformation
- •Generative AI can provide multiple “second opinions” and synthesize data
- •AI may improve diagnostic accuracy and reduce missed findings
- •Patient anxiety (“cyberchondria”) is a real downside if misused
- 27:21 – 28:47
AI autonomy in medicine: autopilot analogy, limits, and the need to restore clinician time
The discussion compares AI in medicine to autonomous cars and aircraft autopilot. Topol predicts AI will augment clinicians significantly but won’t fully cover all of medicine; he also argues AI could help solve the time-crunch that erodes trust and drives concierge models.
- •Autonomy works in constrained conditions; medicine is too variable for full autonomy
- •More realistic near-term model: autopilot with human oversight
- •Patients may increasingly run their data through AI for extra review
- •Clinicians currently lack time; AI could return ‘the gift of time’
- •Time pressure and interruptions degrade care quality and relationships
- 28:47 – 32:59
Reversing aging and living forever: why ‘immortality’ is unlikely and prevention is the pragmatic path
Grant asks whether humans could live forever amid AI hype. Topol argues aging is a process, not a disease; partial rejuvenation might be possible but comes with trade-offs (e.g., tumor risk in animal reprogramming), making prevention of major diseases the most realistic near-term strategy.
- •Topol rejects the idea of human immortality
- •Epigenetic reprogramming shows promise in mice but increases tumor risk
- •AI-driven drug discovery won’t ‘end all diseases’—treatments aren’t usually cures
- •Genome editing for an entire species isn’t realistic
- •Best bet: identify who’s vulnerable to the big three and prevent disease onset
- 32:59 – 38:39
Lightning round: worst advice, sleep as a lever, medical error prevention, and protecting science funding
In closing, Topol critiques common cardiology advice (CT calcium scoring anxiety), elevates sleep as an under-addressed pillar, and shares optimism about preventing age-related disease. The conversation also turns to diagnostic errors, psychological safety in teams, and the urgency of sustained research funding.
- •Worst regular advice (cardiology): CT calcium scores that fuel anxiety without clear value
- •Best tip not covered: improve sleep quality and regularity; tracking can help
- •Topol’s mindset shift: now confident prevention of big diseases is achievable
- •Diagnostic errors are widespread; Grant highlights psychological safety to reduce errors
- •Science funding cuts threaten momentum during a uniquely promising period for biomedicine
